IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma

Creative Commons License

Cairns R. A., Iqbal J., Lemonnier F., KÜÇÜK C., de Leval L., Jais J., ...Daha Fazla

BLOOD, cilt.119, sa.8, ss.1901-1903, 2012 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 119 Sayı: 8
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1182/blood-2011-11-391748
  • Dergi Adı: BLOOD
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1901-1903
  • Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

Mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) occur in most grade 2 and 3 gliomas, secondary glioblastomas, and a subset of acute myelogenous leukemias but have not been detected in other tumor types. The mutations occur at specific arginine residues and result in the acquisition of a novel enzymatic activity that converts 2-oxoglutarate to D-2-hydroxyglutarate. This study reports IDH1 and IDH2 genotyping results from a set of lymphomas, which included a large set of peripheral T-cell lymphomas. IDH2 mutations were identified in approximately 20% of angioimmunoblastic T-cell lymphomas (AITLs), but not in other peripheral T-cell lymphoma entities. These results were confirmed in an independent set of AITL patients, where the IDH2 mutation rate was approximately 45%. This is the second common genetic lesion identified in AITL after TET2 and extends the number of neoplastic diseases where IDH1 and IDH2 mutations may play a role. (Blood. 2012;119(8):1901-1903)